NCT04236765

Brief Summary

In countries with a low incidence of Tuberculosis (TB), the incidence remains higher among the immigrant population than among the autochthonous population beyond the first years after arrival in the host country. In addition, at a pediatric level, most cases are produced in immigrant children and the children of immigrants. This persistence of a greater incidence in the immigrant population might, in part, be explained by the increase in exposure to Mycobacterium tuberculosis during trips to their country of origin to visit friends and relatives (VFRs). The objectives of the study are to estimate the risk of latent infection by M. tuberculosis (LTBI)/TB in children VFRs and the factors associated with this risk. The investigators will also study the behavior of the diagnostic tests. This project will be carried out in collaboration with 21 primary health care centers and 5 hospitals in Catalonia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
492

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

January 10, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 22, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

July 20, 2020

Status Verified

July 1, 2020

Enrollment Period

3 years

First QC Date

January 10, 2020

Last Update Submit

July 17, 2020

Conditions

Keywords

TuberculosisLatent TuberculosisChildrenImmigrantIncidenceTravel-Related InfectionTuberculin TestInterferon-gamma Release Assay

Outcome Measures

Primary Outcomes (1)

  • change in health status: LTBI diagnosis after having traveled abroad

    To be evaluated with Tuberculin test and Interferon-gamma release assay (QuantiFERON-TB Gold Plus (QFT-Plus)). LTBI is defined as having at least one positive infection test (Tuberculin Test and/or QFT-Plus)

    At 8-12 weeks after returning from the travel abroad

Secondary Outcomes (7)

  • Sociodemographic characteristics of the patients

    baseline (before traveling abroad)

  • Epidemiological data (before travel abroad):

    baseline (before travel abroad)

  • Epidemiological data (after travel abroad):

    At 8-12 weeks after returning from the travel abroad

  • Clinical data: Bacillus Calmette-Guerin (BCG) vaccination

    baseline (before travel abroad)

  • Clinical data: presence of BCG scar

    baseline (before travel abroad)

  • +2 more secondary outcomes

Study Arms (1)

TB infection-screening benefiting group

EXPERIMENTAL

children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.

Other: TB infection-screening benefiting group

Interventions

The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.

TB infection-screening benefiting group

Eligibility Criteria

Age6 Months - 14 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Informed consent must be obtained from the parents of legal guardian.
  • Less than 15 years of age.
  • One or both of the parents is from a country with an elevated incidence of TB. A country is considered to have an elevated incidence of TB when this incidence is 3-fold higher than the incidence in Catalunya, that is approximately 40/100,000 inhabitants. Countries with official reports describing an incidence less than the value proposed but which have regions with \> 40 cases /100,000 inhabitants are also included (Table and figure 1)
  • The journey to the country of origin is made by at least one of the parents.
  • The duration of the visit to the country of origin is of at least 21 days.

You may not qualify if:

  • Previous TB or LTBI.
  • Tourist visit to hotels and resorts with scarce contact with the autochthonous population.
  • Primary or secondary immunodeficiency to treatment with corticosteroids, transplantation, treatment with anti-tumor necrosis factor, chronic renal insufficiency.
  • Congenital cardiopathy.
  • Cystic fibrosis of the pancreas and other congenital diseases of pulmonary origin.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitari Mutua Terrassa

Terrassa, Barcelona, 08221, Spain

RECRUITING

Related Publications (1)

  • Soriano-Arandes A, Cayla JA, Goncalves AQ, Orcau A, Noguera-Julian A, Padilla E, Sola-Segura E, Gordillo NR, Espiau M, Garcia-Lerin MG, Rifa-Pujol MA, Jordi Gomez I Prat, Macia-Rieradevall E, Martin-Nalda A, Eril-Rius M, Santos Santiago J, Busquets-Poblet L, Martinez RM, Perez-Porcuna TM. Tuberculosis infection in children visiting friends and relatives in countries with high incidence of tuberculosis: A study protocol. Medicine (Baltimore). 2020 Sep 4;99(36):e22015. doi: 10.1097/MD.0000000000022015.

MeSH Terms

Conditions

Latent TuberculosisTuberculosisTravel-Related Illness

Condition Hierarchy (Ancestors)

Mycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsLatent InfectionSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Tomàs Maria Pérez Porcuna, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 10, 2020

First Posted

January 22, 2020

Study Start

January 1, 2018

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

July 20, 2020

Record last verified: 2020-07

Locations